Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intralesional Allovectin-7 vs dacarbazine or temozolomide in recurrent metastatic melanoma
2007-004120-21Phase 3Terminated
- Sponsor
- Vical Incorporated
- Start
- Sep 2007
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of allovectin-7 in melanoma (2 arms), sponsored by Vical Incorporated. Primary endpoint: Overall response rate at ≥24 weeks. Started Sep 2007; status: terminated.
02
Drugs
allovectin-7
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-004120-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004120-21.